The University of Chicago Header Logo

Connection

George Bakris to Calcium Channel Blockers

Back to Details
This is a "connection" page, showing publications George Bakris has written about Calcium Channel Blockers.
George Bakris
Connection Strength
9.069
Calcium Channel Blockers
  1. Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb; 63(2):220-1.
    View in: PubMed
    Score: 0.445
  2. The author replies. Kidney Int. 2013 Jul; 84(1):215.
    View in: PubMed
    Score: 0.432
  3. The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int. 2013 Jan; 83(1):20-2.
    View in: PubMed
    Score: 0.417
  4. Initial combination antihypertensives: let's ACCELERATE. Lancet. 2011 Jan 22; 377(9762):278-9.
    View in: PubMed
    Score: 0.364
  5. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32.
    View in: PubMed
    Score: 0.295
  6. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
    View in: PubMed
    Score: 0.275
  7. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005 Oct; 46(4):637-42.
    View in: PubMed
    Score: 0.252
  8. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
    View in: PubMed
    Score: 0.240
  9. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42.
    View in: PubMed
    Score: 0.235
  10. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.231
  11. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002.
    View in: PubMed
    Score: 0.230
  12. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61.
    View in: PubMed
    Score: 0.226
  13. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91.
    View in: PubMed
    Score: 0.197
  14. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
    View in: PubMed
    Score: 0.186
  15. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther. 2000 Jun; 14(3):295-301.
    View in: PubMed
    Score: 0.174
  16. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.165
  17. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.155
  18. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96.
    View in: PubMed
    Score: 0.154
  19. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.148
  20. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997 Nov; 12(11):2244-50.
    View in: PubMed
    Score: 0.146
  21. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.145
  22. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8.
    View in: PubMed
    Score: 0.145
  23. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50.
    View in: PubMed
    Score: 0.139
  24. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8.
    View in: PubMed
    Score: 0.138
  25. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.136
  26. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4.
    View in: PubMed
    Score: 0.134
  27. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9.
    View in: PubMed
    Score: 0.130
  28. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62.
    View in: PubMed
    Score: 0.126
  29. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
    View in: PubMed
    Score: 0.125
  30. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
    View in: PubMed
    Score: 0.114
  31. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.107
  32. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med. 1991 Dec; 151(12):2367-72.
    View in: PubMed
    Score: 0.097
  33. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5.
    View in: PubMed
    Score: 0.095
  34. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9.
    View in: PubMed
    Score: 0.094
  35. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991 Jul; 4(7 Pt 2):487S-493S.
    View in: PubMed
    Score: 0.094
  36. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5.
    View in: PubMed
    Score: 0.089
  37. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.085
  38. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.083
  39. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
    View in: PubMed
    Score: 0.079
  40. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57.
    View in: PubMed
    Score: 0.078
  41. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.075
  42. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52.
    View in: PubMed
    Score: 0.074
  43. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev Cardiol. 2008; 11(1):42-9.
    View in: PubMed
    Score: 0.074
  44. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.074
  45. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26.
    View in: PubMed
    Score: 0.069
  46. The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr. 2007; 2(3):207-12.
    View in: PubMed
    Score: 0.069
  47. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
    View in: PubMed
    Score: 0.067
  48. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul; 99(7):431-6.
    View in: PubMed
    Score: 0.066
  49. Is ethnicity a factor in choice of antihypertensive drug? Postgrad Med. 2005 May; 117(5):40.
    View in: PubMed
    Score: 0.061
  50. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.061
  51. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.060
  52. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
    View in: PubMed
    Score: 0.059
  53. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5.
    View in: PubMed
    Score: 0.056
  54. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
    View in: PubMed
    Score: 0.056
  55. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
    View in: PubMed
    Score: 0.054
  56. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8.
    View in: PubMed
    Score: 0.054
  57. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.052
  58. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
    View in: PubMed
    Score: 0.051
  59. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.050
  60. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7.
    View in: PubMed
    Score: 0.048
  61. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
    View in: PubMed
    Score: 0.047
  62. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001 May; 37(5):1268-72.
    View in: PubMed
    Score: 0.046
  63. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70.
    View in: PubMed
    Score: 0.043
  64. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60.
    View in: PubMed
    Score: 0.040
  65. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
    View in: PubMed
    Score: 0.037
  66. Hypertension. Nat Rev Dis Primers. 2018 03 22; 4:18014.
    View in: PubMed
    Score: 0.037
  67. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 2:S34-40.
    View in: PubMed
    Score: 0.037
  68. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42.
    View in: PubMed
    Score: 0.035
  69. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
    View in: PubMed
    Score: 0.035
  70. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother. 1996 Jul-Aug; 30(7-8):791-801.
    View in: PubMed
    Score: 0.033
  71. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep. 2014 Mar; 16(3):419.
    View in: PubMed
    Score: 0.028
  72. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993 May; 33(5):392-9.
    View in: PubMed
    Score: 0.027
  73. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.024
  74. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
    View in: PubMed
    Score: 0.021
  75. The evolution of antihypertensive therapy: an overview of four decades of experience. J Am Coll Cardiol. 1989 Dec; 14(7):1595-608.
    View in: PubMed
    Score: 0.021
  76. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.021
  77. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
    View in: PubMed
    Score: 0.018
  78. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
    View in: PubMed
    Score: 0.018
  79. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4.
    View in: PubMed
    Score: 0.017
  80. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
    View in: PubMed
    Score: 0.014
  81. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
    View in: PubMed
    Score: 0.014
  82. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.013
  83. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.